• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

Opinion
Video

Experts discuss oral SERDs in the pipeline, clinical pathways for treatment of breast cancer, and strategies to help ensure patients have access to treatment. The participants also describe diverse agents in development, including their toxicity profiles.

This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.

Mardones addresses strategies to reduce barriers to medication access, with Callahan emphasizing the role of clinical pathways in streamlining ESR1 mutation testing documentation. Vidal discusses oral selective estrogen receptor degraders (SERDs) in development, highlighting differences in toxicity profiles among agents and expressing anticipation for these options in clinical practice. Gradishar explores the evolving landscape of new agents. The discussion emphasizes the need for differentiation and efficacy data among emerging drugs, which promise an exciting era with expanded treatment options for patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) breast cancer. Concluding the peer exchange, each expert shares their final thoughts, celebrating the current and upcoming advancements in ER+/HER– breast cancer therapeutics, focusing on their efficacy, tolerability, and potential to improve patient outcomes and quality of life. Stay informed about the evolving landscape of breast cancer treatments and explore the promising future of tailored therapies.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Ronesh Sinha, MD
Yuqian Liu, PharmD
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
dr monica li
dr lawrence eichenfield
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Video 13 - "Measuring Implicit Bias"
Dr Michael Morse, Duke University
Video 10 - "Bronchiectasis Exacerbation Management"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.